| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Diagnostic Techniques | 3 | 2020 | 73 | 1.220 |
Why?
|
| Colonic Neoplasms | 18 | 2020 | 573 | 1.170 |
Why?
|
| Pathology, Molecular | 4 | 2017 | 34 | 0.980 |
Why?
|
| ErbB Receptors | 9 | 2017 | 501 | 0.630 |
Why?
|
| Pancreatic Cyst | 1 | 2017 | 28 | 0.600 |
Why?
|
| Telomere | 1 | 2017 | 114 | 0.560 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2016 | 101 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 1265 | 0.520 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2014 | 282 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 669 | 0.470 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2013 | 108 | 0.440 |
Why?
|
| Transcription, Genetic | 5 | 2013 | 1157 | 0.430 |
Why?
|
| Neoplasms | 3 | 2016 | 3041 | 0.390 |
Why?
|
| Colitis | 4 | 2020 | 244 | 0.370 |
Why?
|
| Genes, ras | 7 | 2019 | 98 | 0.370 |
Why?
|
| MicroRNAs | 4 | 2020 | 551 | 0.350 |
Why?
|
| Genetic Variation | 1 | 2016 | 1374 | 0.330 |
Why?
|
| Precancerous Conditions | 5 | 2012 | 200 | 0.320 |
Why?
|
| Mutation | 10 | 2019 | 4143 | 0.310 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 1431 | 0.260 |
Why?
|
| Sarcoma, Myeloid | 2 | 2015 | 15 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2014 | 665 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 481 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 6 | 2009 | 99 | 0.220 |
Why?
|
| Prognosis | 5 | 2016 | 3783 | 0.210 |
Why?
|
| Humans | 39 | 2020 | 89357 | 0.200 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 529 | 0.190 |
Why?
|
| Azoxymethane | 7 | 2011 | 84 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2013 | 91 | 0.190 |
Why?
|
| Ursodeoxycholic Acid | 3 | 2008 | 25 | 0.180 |
Why?
|
| ras Proteins | 4 | 2014 | 130 | 0.180 |
Why?
|
| Transplantation Conditioning | 3 | 2013 | 374 | 0.180 |
Why?
|
| RNA | 1 | 2004 | 580 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 793 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1549 | 0.170 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 60 | 0.170 |
Why?
|
| Receptors, CXCR4 | 2 | 2016 | 45 | 0.170 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 64 | 0.170 |
Why?
|
| Losartan | 1 | 2019 | 30 | 0.170 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 15 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2020 | 120 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 41 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 39 | 0.160 |
Why?
|
| DNA-Binding Proteins | 5 | 2013 | 1242 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2758 | 0.160 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 177 | 0.150 |
Why?
|
| Colon | 4 | 2014 | 510 | 0.150 |
Why?
|
| Receptors, Calcitriol | 2 | 2019 | 130 | 0.150 |
Why?
|
| Telomere Homeostasis | 1 | 2017 | 30 | 0.150 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 2366 | 0.150 |
Why?
|
| Hyaluronan Receptors | 1 | 1997 | 38 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 340 | 0.150 |
Why?
|
| Telomerase | 1 | 2017 | 62 | 0.150 |
Why?
|
| Vitamin D | 1 | 2019 | 269 | 0.140 |
Why?
|
| ADAM17 Protein | 1 | 2016 | 9 | 0.140 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 16 | 0.140 |
Why?
|
| Colitis, Ulcerative | 3 | 2013 | 739 | 0.140 |
Why?
|
| Mice | 15 | 2020 | 11761 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 45 | 0.130 |
Why?
|
| Adenoma | 2 | 2010 | 246 | 0.130 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 49 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 136 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 414 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1997 | 159 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 106 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2014 | 447 | 0.130 |
Why?
|
| Cholecalciferol | 2 | 2007 | 35 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 332 | 0.130 |
Why?
|
| Transcription Factors | 6 | 2014 | 1653 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2014 | 22 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2014 | 164 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 2415 | 0.120 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2014 | 55 | 0.120 |
Why?
|
| Indazoles | 1 | 2015 | 67 | 0.120 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2016 | 50 | 0.120 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 34 | 0.120 |
Why?
|
| Iodine Radioisotopes | 1 | 2015 | 134 | 0.120 |
Why?
|
| Cytogenetic Analysis | 1 | 2014 | 71 | 0.120 |
Why?
|
| Incidental Findings | 1 | 2015 | 98 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 78 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2014 | 96 | 0.120 |
Why?
|
| Imidazoles | 1 | 2015 | 148 | 0.120 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 81 | 0.120 |
Why?
|
| Immunohistochemistry | 7 | 2013 | 1799 | 0.110 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 3 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 198 | 0.110 |
Why?
|
| Animals | 21 | 2020 | 27371 | 0.110 |
Why?
|
| Haplotypes | 2 | 2013 | 637 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 193 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 461 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 159 | 0.110 |
Why?
|
| Dextran Sulfate | 2 | 2011 | 68 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 605 | 0.110 |
Why?
|
| Pancreatitis | 1 | 2013 | 86 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 102 | 0.110 |
Why?
|
| Lymphoma | 2 | 2012 | 265 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 55 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2019 | 8241 | 0.110 |
Why?
|
| Down-Regulation | 4 | 2020 | 519 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2013 | 111 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 390 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 173 | 0.100 |
Why?
|
| Up-Regulation | 5 | 2020 | 727 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 112 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1719 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2016 | 383 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2012 | 10 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 416 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2013 | 166 | 0.100 |
Why?
|
| Graft vs Host Disease | 2 | 2011 | 360 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 435 | 0.100 |
Why?
|
| Middle Aged | 14 | 2019 | 25974 | 0.100 |
Why?
|
| HIV | 1 | 2011 | 48 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 866 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2008 | 13 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2012 | 151 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 249 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2011 | 45 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 64 | 0.100 |
Why?
|
| Male | 19 | 2019 | 42411 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 2362 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.100 |
Why?
|
| Graft Survival | 2 | 2013 | 900 | 0.090 |
Why?
|
| Curriculum | 1 | 2016 | 568 | 0.090 |
Why?
|
| Inflammation | 2 | 2020 | 972 | 0.090 |
Why?
|
| Viral Load | 1 | 2011 | 145 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1150 | 0.090 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 20 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 160 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2015 | 0.090 |
Why?
|
| RNA, Messenger | 7 | 2013 | 2017 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2011 | 130 | 0.090 |
Why?
|
| Aged | 11 | 2019 | 19165 | 0.090 |
Why?
|
| Paxillin | 1 | 2010 | 59 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2011 | 317 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 2566 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 424 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 726 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2013 | 423 | 0.090 |
Why?
|
| Female | 17 | 2019 | 46202 | 0.090 |
Why?
|
| Cyclin D1 | 3 | 2007 | 84 | 0.090 |
Why?
|
| Signal Transduction | 9 | 2016 | 3385 | 0.090 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 81 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 887 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 84 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2009 | 63 | 0.080 |
Why?
|
| Adult | 11 | 2019 | 26607 | 0.080 |
Why?
|
| Colonic Polyps | 1 | 2010 | 132 | 0.080 |
Why?
|
| Enzyme Precursors | 1 | 1988 | 21 | 0.080 |
Why?
|
| Cathepsins | 1 | 1988 | 21 | 0.080 |
Why?
|
| Transformation, Genetic | 1 | 1988 | 41 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2017 | 1194 | 0.080 |
Why?
|
| Transcriptome | 1 | 2013 | 630 | 0.080 |
Why?
|
| Diet | 1 | 2011 | 442 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2008 | 115 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2558 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 125 | 0.070 |
Why?
|
| Immediate-Early Proteins | 3 | 1994 | 165 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 695 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2340 | 0.070 |
Why?
|
| Young Adult | 6 | 2019 | 6312 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 540 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 1412 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2019 | 2001 | 0.060 |
Why?
|
| Adenoma, Villous | 1 | 2005 | 2 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 922 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2019 | 682 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 981 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2017 | 267 | 0.060 |
Why?
|
| Transplantation, Homologous | 3 | 2013 | 996 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 148 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6811 | 0.060 |
Why?
|
| Apoptosis | 3 | 2019 | 1717 | 0.060 |
Why?
|
| Reference Standards | 1 | 2004 | 144 | 0.060 |
Why?
|
| Transfection | 3 | 2012 | 911 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 36 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 3011 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2013 | 44 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 890 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1862 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 274 | 0.050 |
Why?
|
| Retroviridae | 2 | 2013 | 79 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 794 | 0.050 |
Why?
|
| Ligands | 2 | 2016 | 445 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 3218 | 0.050 |
Why?
|
| Cadherins | 1 | 2002 | 163 | 0.050 |
Why?
|
| HCT116 Cells | 2 | 2012 | 155 | 0.050 |
Why?
|
| Rats | 5 | 2011 | 4041 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2020 | 657 | 0.050 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1652 | 0.050 |
Why?
|
| Reference Values | 2 | 2002 | 661 | 0.050 |
Why?
|
| Laboratories, Hospital | 1 | 2020 | 8 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 22 | 0.040 |
Why?
|
| Base Sequence | 4 | 2008 | 2327 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 49 | 0.040 |
Why?
|
| Intestinal Mucosa | 3 | 2013 | 805 | 0.040 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 82 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 153 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 1057 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 46 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 38 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1574 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 56 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 83 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 1534 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2019 | 150 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1769 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2008 | 33 | 0.040 |
Why?
|
| Mice, Inbred A | 2 | 2007 | 23 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2010 | 146 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 784 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 90 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 425 | 0.030 |
Why?
|
| Spiro Compounds | 1 | 2016 | 25 | 0.030 |
Why?
|
| Diet, Western | 1 | 2016 | 38 | 0.030 |
Why?
|
| Quinazolines | 2 | 2008 | 221 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2011 | 269 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2008 | 154 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 76 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1998 | 433 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2011 | 313 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 1997 | 502 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 166 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 78 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 85 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 46 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 969 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 134 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 101 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2016 | 211 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2014 | 93 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 52 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 173 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1214 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 24 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 95 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 1994 | 53 | 0.030 |
Why?
|
| Cell Division | 2 | 2007 | 696 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 80 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 3027 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 294 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 618 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 66 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 98 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 131 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2013 | 67 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 509 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 445 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 98 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 392 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2012 | 174 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 443 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2013 | 478 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 446 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 393 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 29 | 0.020 |
Why?
|
| Rotation | 1 | 2011 | 91 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2012 | 112 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 465 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1991 | 65 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 65 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 159 | 0.020 |
Why?
|
| Macrophages | 1 | 2014 | 571 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 370 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 117 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 401 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 394 | 0.020 |
Why?
|
| Mucin-6 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 762 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 55 | 0.020 |
Why?
|
| Illinois | 1 | 2011 | 480 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 208 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 354 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2010 | 152 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 85 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 740 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 134 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2010 | 84 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 157 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 2018 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1597 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1994 | 739 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 343 | 0.020 |
Why?
|
| Fibroblasts | 2 | 1991 | 755 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 245 | 0.020 |
Why?
|
| Early Growth Response Protein 1 | 3 | 1994 | 56 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 871 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 123 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2009 | 133 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 7 | 0.020 |
Why?
|
| Cyclin D | 1 | 2008 | 14 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1988 | 97 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2009 | 266 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 369 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1991 | 2062 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 243 | 0.020 |
Why?
|
| Cholic Acid | 1 | 2008 | 7 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 65 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1988 | 155 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 83 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3666 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 85 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1991 | 956 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 543 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 950 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1120 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2008 | 92 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1714 | 0.020 |
Why?
|
| United States | 1 | 2020 | 6989 | 0.020 |
Why?
|
| Leukemia | 1 | 2009 | 323 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2009 | 353 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1988 | 646 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2008 | 125 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1595 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 123 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 576 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 1184 | 0.020 |
Why?
|
| Carcinogens | 1 | 2007 | 111 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 126 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 198 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2401 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2016 | 1045 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 67 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 85 | 0.020 |
Why?
|
| DNA | 2 | 1991 | 1308 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 836 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 19 | 0.020 |
Why?
|
| beta Catenin | 1 | 2007 | 266 | 0.020 |
Why?
|
| Rabbits | 2 | 1998 | 639 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 345 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 1146 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 1489 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 9057 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 101 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 362 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2884 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 327 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 233 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 5338 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 1237 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1998 | 46 | 0.010 |
Why?
|
| Cell Line | 2 | 1994 | 2496 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 293 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 375 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 9263 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1998 | 167 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1998 | 241 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1998 | 319 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1998 | 389 | 0.010 |
Why?
|
| Early Growth Response Protein 2 | 1 | 1994 | 17 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1994 | 87 | 0.010 |
Why?
|
| Tyrosine | 1 | 1994 | 133 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1993 | 44 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1994 | 116 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1994 | 237 | 0.010 |
Why?
|
| Calcium | 1 | 1998 | 1175 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1994 | 261 | 0.010 |
Why?
|
| Methylation | 1 | 1993 | 268 | 0.010 |
Why?
|
| Early Growth Response Protein 3 | 1 | 1991 | 1 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 1994 | 269 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1991 | 58 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1994 | 1088 | 0.010 |
Why?
|
| Haplorhini | 1 | 1991 | 81 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1994 | 1132 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1994 | 751 | 0.010 |
Why?
|
| Gene Expression | 1 | 1994 | 1310 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 1076 | 0.000 |
Why?
|